Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GRM5 | P41594 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652949 | 1.00 | MEN1 (0.70) | MEN1KMT2ALMNAATML3MBTL1 | |
| SCHEMBL11244247 | 0.83 | MEN1 (1.00) | MEN1KMT2ALMNAATML3MBTL1 | |
| SCHEMBL2470064 | 0.81 | MEN1 (0.84) | MEN1KMT2ALMNAATML3MBTL1 | |
| SCHEMBL4968581 | 0.78 | GRM5 (0.53) | MEN1KMT2AALDH1A1GRM5GAA | |
| SCHEMBL4968588 | 0.78 | GRM5 (0.53) | MEN1KMT2AALDH1A1GRM5GAA | |
| SCHEMBL3213423 | 0.76 | MEN1 (0.70) | MEN1KMT2ALMNAATML3MBTL1 | |
| SCHEMBL4970899 | 0.76 | GRM5 (0.55) | MEN1KMT2ALMNAL3MBTL1ALDH1A1 | |
| SCHEMBL5653492 | 0.76 | GRM5 (0.55) | MEN1KMT2ALMNAL3MBTL1ALDH1A1 | |
| SCHEMBL10210736 | 0.75 | MEN1 (0.68) | MEN1KMT2ALMNAATML3MBTL1 | |
| SCHEMBL5654183 | 0.73 | NPC1 (0.54) | MEN1KMT2AL3MBTL1GRM5GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | claimed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | PDE7A, PDE10A, PDE7B | MEN1 415/4885KMT2A 3459/4885LMNA 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.